Current Regulatory Standpoint on Evaluating the Bioequivalence of Different Classes of Generic Drugs - Is the Evaluation in the Right Direction?

Author(s): Francis Micheal, Mohanlal Sayana, Balamurali Musuvathi Motial*

Journal Name: Current Drug Metabolism

Volume 20 , Issue 10 , 2019


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

Background: The concept of evaluating bioequivalence has changed over a period of time. Currently, the Average Bioequivalence approach (ABE) is the gold standard tool for the evaluation of generics. Of late, many debates had arisen about employing ABE approach for the appraisal of all drug categories. This review aims to examine the limitations of ABE approach and the significances of Population Bioequivalence (PBE) and Individual Bioequivalence (IBE) approach, current regulatory thinking for assessing different categories of the drug, whether they are adequately assessed, and the evaluation is in the right direction.

Methods: We carried out an organized search of bibliographic databases for peer-reviewed research literatures, regulatory recommendations, guidance documents using a focused review question and eligibility criteria. The standard tools were used to appraise the quality of retrieved documents and to make sure the authenticity of the data.

Results: In total 73 references were used in the review, the majority of the references (guidance documents) were from the different regulatory agencies and product-specific guidance. There were 29 product-specific guidance from USFDA and EMA. The limitations of the ABE approach were discussed in detail along with the significances of Population Bioequivalence (PBE) approach and Individual Bioequivalence (IBE) approaches.

Conclusion: It is apparent from the review that IBE approach is a precise method for evaluating the drugs as it answers drug interchangeability (prescribability and switchability). IBE approach is followed by PBE approach and ABE approach for the evaluation of different categories of drugs in terms of precision.

Keywords: Critical dose drugs, average bioequivalence, individual bioequivalence, population bioequivalence, drug interchangeability, prescribability, switchability.

[1]
U.S. Food and Drug Administration, Generic Drugs. 2019.https://www.fda.gov/drugs/buying-using-medicine-safely/generic-drugs (Accessed June 21, 2019).
[2]
U.S. Food and Drug Administration, Generic Drugs: What Everyone Should Know. 2016.http://www.fda.gov/Drugs/Resources ForYou/ucm134154.htm (Accessed June 21, 2019).
[3]
U.S. Food and Drug Administration, The history of drug regulation in the United States. https://www.fda.gov/media/73549/download (Accessed June 21, 2019).
[4]
Welage, L.S.; Kirking, D.M.; Ascione, F.J.; Gaither, C.A. Understanding the scientific issues embedded in the generic drug approval process. J. Am. Pharm. Assoc. (Wash), 2001, 41(6), 856-867.
[http://dx.doi.org/10.1016/S1086-5802(16)31327-4] [PMID: 11765111]
[5]
ANVISA, Resolution No. 9787 of Feb 11, 1999, Official diary of the union. http://www.planalto.gov.br/ccivil_03/leis/l9787.htm (Accessed June 21, 2019).
[6]
ANVISA, Resolution No. 391 of August 9, 1999, Technical regulation for general medicinal products. 1999.http://bvsms.saude.gov. br/bvs/saudelegis/anvisa/1999/res0391_09_08_1999.html (Accessed June 21, 2019).
[7]
Zariffa, N.M.D.; Patterson, S.D. Population and individual bioequivalence: Lessons from real data and simulation studies. J. Clin. Pharmacol., 2001, 41(8), 811-822.
[http://dx.doi.org/10.1177/00912700122010708] [PMID: 11504268]
[8]
ANVISA, Resolution No. 898 of May 29, 2003, Guide for planning and carrying out the statistical stage of studies of relative bioavailability/ bioequivalence. http://portal.anvisa.gov.br/legislacao/?inheritRedirect=true#/visualizar/27340 (Accessed Nov 4, 2019).
[9]
Endrenyi, L.; Midha, K.K. Individual bioequivalence--has its time come? Eur. J. Pharm. Sci., 1998, 6(4), 271-278.
[http://dx.doi.org/10.1016/S0928-0987(97)10021-5] [PMID: 9795081]
[10]
Tothfalusi, L.; Endrenyi, L. Limits for the scaled average bioequivalence of highly variable drugs and drug products. Pharm. Res., 2003, 20(3), 382-389.
[http://dx.doi.org/10.1023/A:1022695819135] [PMID: 12669957]
[11]
Wijnand, H.P. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies. Comput. Methods Programs Biomed., 2003, 70(1), 21-35.
[http://dx.doi.org/10.1016/S0169-2607(02)00019-6] [PMID: 12468124]
[12]
Food and Drug Administration. Draft Guidance: Average, Population and Individual Approaches to Establishment Bioequivalence. 1999.https://www.federalregister.gov/documents/1999/09/08/99-23228/draft-guidance-for-industry-on-average-population-and-individual-approaches-to-establishing (Accessed Nov 4, 2019).
[13]
Federal Register/ Guidance for Industry on Statistical Approaches to Establishing Bioequivalence; Availability Food and Drug Administration. 2001.https://www.federalregister.gov/documents/2001/02/02/01-2789/ guidance-for-industry-on-statistical-approaches-to-establishingbioequivalence- availability (Accessed June 22, 2019).
[14]
Coleman; Michael, D. Human Drug Metabolism: An Introduction, John Wiley & Sons: New Jersey. 2010.
[15]
Generic Substitution of Narrow Therapeutic Index Drugs. 2009.https://www.uspharmacist.com/article/generic-substitution-of-narrow-therapeutic-index-drugs (Accessed June 22, 2019).
[16]
Committee for Medicinal Products for Human Use (CHMP): Guideline on the investigation of bioequivalence, London, 20 January 2010; Doc. Ref.: CPMP/EWP/QWP/1401/98 Rev. 1/ Corr **. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf (Accessed June 22, 2019).
[17]
Chow, S.C. Statistical Methods for Assessment of Individual/ Population Bioequivalence. 2003.https://pdfs.semanticscholar.org/4ae8/83ed90ce3e3959c4e6e395bb733588bf6678.pdf (Accessed June 22, 2019).
[18]
Idkaidek, N.M.; Al-Ghazawi, A.; Najib, N.M. Bioequivalence evaluation of two brands of amoxicillin/clavulanic acid 250/125 mg combination tablets in healthy human volunteers: Use of replicate design approach. Biopharm. Drug Dispos., 2004, 25(9), 367-372.
[http://dx.doi.org/10.1002/bdd.422] [PMID: 15495146]
[19]
[20]
Henderson, J.D.; Esham, R.H. Generic substitution: Issues for problematic drugs. South. Med. J., 2001, 94(1), 16-21.
[http://dx.doi.org/10.1097/00007611-200194010-00003] [PMID: 11213935]
[21]
Wijnand, H.P. Assessment of average, population and individual bioequivalence in two- and four-period crossover studies. Comput. Methods Programs Biomed., 2003, 70(1), 21-35.
[http://dx.doi.org/10.1016/S0169-2607(02)00019-6] [PMID: 12468124]
[22]
Endrenyi, L.; Midha, K.K. Individual bioequivalence-has its time come? Eur. J. Pharm. Sci., 1998, 6(4), 271-278.
[http://dx.doi.org/10.1016/S0928-0987(97)10021-5] [PMID: 9795081]
[23]
Zariffa, N.M.D.; Patterson, S.D. Population and individual bioequivalence: Lessons from real data and simulation studies. J. Clin. Pharmacol., 2001, 41(8), 811-822.
[http://dx.doi.org/10.1177/00912700122010708] [PMID: 11504268]
[24]
Meredith, P. Bioequivalence and other unresolved issues in generic drug substitution. Clin. Ther., 2003, 25(11), 2875-2890.
[http://dx.doi.org/10.1016/S0149-2918(03)80340-5] [PMID: 14693311]
[25]
Food and Drug Administration/Draft Guidance; Average, Population and Individual Approaches to Establishment Bioequivalence., CDER, Food and Drug Administration: Rockville, MD. 1999.
[26]
Guidelines for Bioavailability and Bioequivalence Studies, CDSCO, Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, New Delhi, March. 2005.https://web.archive.org/web/20140327185526/http://drugscontrol.org/GFBBS.pdf (Accessed June 22, 2019).
[27]
Guidance for Industry Statistical Approaches to Establishing Bioequivalence, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), January. 2001.https://www.fda.gov/media/70958/download (Accessed June 21, 2019).
[28]
Guidance for Industry Bioavailability and Bioequivalence Studies for Orally administered Drug Products - General Considerations, U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), March. 2003.https://www.ipqpubs.com/wp-content/uploads/2014/04/BABEOld. pdf (Accessed June 22, 2019).
[29]
U.S. Food and Drug Administration, Product Specific Guidance for Progesterone. 2011.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Progesterone_caps_19781_RC02-11.pdf (Accessed June 21, 2019).
[30]
U.S. Food and Drug Administration, Product Specific Guidance for Alendronate Sodium; Cholecalciferol. 2011.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alendronate_Cholecalciferol_tab_21762_RC4-09.pdf (Accessed June 21, 2019).
[31]
U.S. Food and Drug Administration, Product Specific Guidance for Alendronate Sodium. 2011.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Alendronate__Sodium_tab_20560_RC1-08.pdf (Accessed June 21, 2019).
[32]
U.S. Food and Drug Administration, Product Specific Guidance for Amlodipine Besylate. 2008.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amlodipine_Besylate_tab_19787_RC6-03.pdf (Accessed June 21, 2019).
[33]
U.S. Food and Drug Administration, Product Specific Guidance for Amlodipine Besylate; Atorvastatin Calcium. 2009.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amlodipine_Besylate;_Atorvastatin_Calcium_tab_21540_RC5-09.pdf (Accessed June 21, 2019).
[34]
U.S. Food and Drug Administration, Product Specific Guidance for Rabeprazole Sodium DR Capsule. 2014.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rabeprazole%20sodium_DRcap_204736_RC02-14.pdf (Accessed June 21, 2019).
[35]
U.S. Food and Drug Administration, Product Specific Guidance for Rabeprazole Sodium DR Tablet. 2010.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Rabeprazole_Sodium_DRTab_20973_RC12-10.pdf (Accessed June 21, 2019).
[36]
U.S. Food and Drug Administration, Product Specific Guidance for Esomeprazole magnesium powder for delayed-release suspension. 2018.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole%20magnesium_oral%20DR%20suspension_NDA%20021957%20and%20022101_RV11-17.pdf (Accessed June 21, 2019).
[37]
U.S. Food and Drug Administration, Product Specific Guidance for Esomeprazole Magnesium; Naproxen DR Tablet. 2011.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Esomeprazole_Mag;_Naproxen_DRtab_22511_RC03-11.pdf (Accessed June 21, 2019).
[38]
U.S. Food and Drug Administration, Product Specific Guidance for Esomeprazole Strontium DR Capsule. 2014.http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM406265.pdf (Accessed June 21, 2019).
[39]
Committee for Medicinal Products for Human Use (CHMP)/ Guideline on the pharmacokinetic and clinical evaluation of modified release dosage forms (EMA/CPMP/EWP/280/96 Corr1), 20 November. 2014.EMA/CHMP/EWP/280/96. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmacokinetic-clinical-evaluation-modified-release-dosage-forms_en.pdf (Accessed June 22, 2019).
[40]
Therapeutic Goods Administration/ Scientific Guidelines. https://www.tga.gov.au/clinical-efficacy-and-safety-guidelines (Accessed June 21, 2019).
[41]
Generic Medicines and Bioequivalence, March. 2013.https://medsafe.govt.nz/profs/PUArticles/Mar2013GenericMedBioqueivalence.htm (Accessed June 21, 2019).
[42]
Guidance Document, Conduct and Analysis of Comparative Bioavailability Studies, Published by authority of the Minister of Health, Adopted Date 2012/02/08, Effective Date; 2012./05/22. (https://www.canada.ca/en/health-canada/services/drugs-healthproducts/drug-products/applications-submissions/guidancedocuments/bioavailability-bioequivalence/conduct-analysiscomparative.html) (Accessed June 22, 2019).
[43]
Guidance Document, Comparative Bioavailability Standards: Formulations Used for Systemic Effects, Adopted Date 2012/02/08, Effective Date; 2012./05/22. (https://www.canada.ca/en/health-canada/services/drugs-healthproducts/drug-products/applications-submissions/guidancedocuments/bioavailability-bioequivalence/comparativebioavailability-standards-formulations-used-systemic-effects.html) (Accessed June 22, 2019).
[44]
Medicines Control Council, Biostudies, Version 5, June. 2011.http://www.rrfa.co.za/wp-content/uploads/2012/11/2.06-Biostudies-Jun11-v5.pdf (Accessed June 22, 2019).
[45]
Multisource (Generic) Pharmaceutical Products; guidelines on registration requirements to establish interchangeability, world health organization mondiale de la sante, working document, QAS/04.093/Rev.4. 2005.https://www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf (Accessed June 22, 2019).
[46]
Guideline for Bioequivalence Studies of Generic Products, NIHS, December. 2006.http://www.nihs.go.jp/drug/be-guide(e)/Generic/GL-E_120229_BE.pdf (Accessed June 22, 2019).
[47]
Guideline for Bioequivalence Studies for Different Strengths of Oral Solid Dosage Forms, NIHS, 24, December. 2006.http://www.nihs.go.jp/drug/be-guide(e)/strength2006e.pdf (Accessed June 22, 2019).
[48]
ANVISA, Resolution No. 1170 of April 19, 2006, determines the publication of the guide to tests of relative bioavailability/ Bioequivalence of Medicines. http://portal.anvisa.gov.br/legislacao/?inheritRedirect=true#/visualizar/27882 (Accessed Nov 4, 2019).
[49]
ANVISA, Resolution No. 478 of March 19, 2002, Guide for bioequivalence studies of generic drugs.
[50]
ANVISA, Resolution No. 479 of March 19, 2002, Guide for protocol and technical report of bioavailability study.
[51]
ANVISA Resolution No. 484 of March 19, 2002, Guide for designs applicable to bioequivalence studies.
[52]
ANVISA, Resolution No. 895 of May 29, 2003, Guide for design of technical report of relative bioavailability/ bioequivalence study. http://portal.anvisa.gov.br/legislacao/?inheritRedirect=true#/visualizar/27334 (Accessed Nov 4, 2019).
[53]
U.S. Food and Drug Administration, Product Specific Guidance for Warfarin. 2012.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Warfarin_Sodium_tab_09218_RC12-12.pdf (Accessed Nov 4, 2019).
[54]
U.S. Food and Drug Administration, Product Specific Guidance for Tacrolimus. 2012.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tacrolimus_cap_50708_RV12-12.pdf (Accessed June 21, 2019).
[55]
U.S. Food and Drug Administration, Product Specific Guidance for Tacrolimus. 2014.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tacrolimus_ERcap_204096_RC07-14.pdf (Accessed June 21, 2019).
[56]
U.S. Food and Drug Administration, Product Specific Guidance for Sirolimus. 2015.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sirolimus_oral%20tablet_021110_RV09-15.pdf (Accessed June 21, 2019).
[57]
U.S. Food and Drug Administration, Product Specific Guidance for Carbamazepine. 2015.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_oral%20suspension_18927_RV03-15.pdf (Accessed June 21, 2019).
[58]
U.S. Food and Drug Administration, Product Specific Guidance for Carbamazepine. 2015.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Carbamazepine_Oral%20ER%20cap_20712_RV03-15.pdf (Accessed June 21, 2019).
[59]
U.S. Food and Drug Administration, Product Specific Guidance for Dabigatran Etexilate Mesylate. 2017.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Dabigatran%20etexilate%20mesylate_oral%20capsule_NDA%20022512_RV05-17.pdf (Accessed June 21, 2019).
[60]
U.S. Food and Drug Administration, Product Specific Guidance for Levothyroxine Sodium Capsule. 2018.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Levothyroxine_Sodium%20capsules_NDA%20021924_RC%20Oct%202018.pdf (Accessed June 21, 2019).
[61]
U.S. Food and Drug Administration, Product Specific Guidance for Phenytoin Sodium ER Capsule. 2014.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Phenytoin_sodium_ERcap_040298_RV12-14.pdf (Accessed June 21, 2019).
[62]
U.S. Food and Drug Administration, Product Specific Guidance for Tacrolimus Granules For Oral Suspension. 2015.http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/10/WC500195127.pdf (Accessed June 21, 2019).
[63]
U.S. Food and Drug Administration, Product Specific Guidance for Sirolimus, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/11/WC500154323.pdf (Accessed June 21, 2019).
[64]
Welage, L.S.; Kirking, D.M.; Ascione, F.J.; Gaither, C.A. Understanding the scientific issues embedded in the generic drug approval process. J. Am. Pharm. Assoc. (Wash), 2001, 41(6), 856-867.
[http://dx.doi.org/10.1016/S1086-5802(16)31327-4] [PMID: 11765111]
[65]
Barrett, J.S.; Batra, V.; Chow, A.; Cook, J.; Gould, A.L.; Heller, A.H.; Lo, M.W.; Patterson, S.D.; Smith, B.P.; Stritar, J.A.; Vega, J.M.; Zariffa, N. PhRMA perspective on population and individual bioequivalence. J. Clin. Pharmacol., 2000, 40(6), 561-570.
[http://dx.doi.org/10.1002/j.1552-4604.2000.tb05980.x] [PMID: 10868305]
[66]
U.S. Food and Drug Administration, Product Specific Guidance for Budesonide; Formoterol Fumarate Dihydrate. 2015.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Budesonide%20and%20Formoterol%20fumarate%20dihydrate_MDI_021929_RC06-15.pdf (Accessed June 21, 2019).
[67]
U.S. Food and Drug Administration, Product Specific Guidance for Amphotericin B. 2016.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Amphotericin%20B_%20Liposomal%20injection_RLD%20050740_RV01-16.pdf (Accessed June 21, 2019).
[68]
U.S. Food and Drug Administration, Product Specific Guidance for Doxorubicin Hydrochloride. 2018.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Doxorubicin%20Hydrochloride_draft_Injection%20injec%20lipo_RLD%2050718_RC09-18.pdf (Accessed June 21, 2019).
[69]
U.S. Food and Drug Administration, Product Specific Guidance for Albuterol Sulfate. 2016.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Albuterol%2 0sulfate_metered%20inhalation%20aerosol_RLD%2020503; %2020983;%2021457_RV12-16.pdf (Accessed June 21, 2019).
[70]
U.S. Food and Drug Administration, Product Specific Guidance for Iron Sucrose Injection. 2013.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Iron_sucrose_inj_21135_RV11-13.pdf (Accessed June 21, 2019).
[71]
U.S. Food and Drug Administration, Product Specific Guidance for Sodium Ferric Gluconate Complex Injection. 2013.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Sodium_ferric_gluconate_complex_inj_20955_RC06-13.pdf (Accessed June 21, 2019).
[72]
U.S. Food and Drug Administration, Product Specific Guidance for Ferumoxytol Injection. 2012.https://www.accessdata.fda.gov/drugsatfda_docs/psg/Ferumoxytol_ivsol_22180_RC12-12.pdf (Accessed June 21, 2019).
[73]
U.S. Food and Drug Administration, Product Specific Guidance for Ferric Carboxymaltose Injection. 2016.https://www.accessdata.fda.gov/drugsatfda_docs/psg/FERRIC%20CARBOXYMALTOSE_injection_RLD%20203565_RC04-16.pdf (Accessed June 21, 2019).


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 20
ISSUE: 10
Year: 2019
Published on: 12 December, 2019
Page: [835 - 844]
Pages: 10
DOI: 10.2174/1389200220666191007152542
Price: $65

Article Metrics

PDF: 41
HTML: 6